Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2005-04-27
2011-10-04
Wax, Robert A (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S423000, C600S483000
Reexamination Certificate
active
08029815
ABSTRACT:
Described herein is the use of ribonucleotide reductase inhibitors in the prevention or treatment of restenosis and other vascular proliferative disorders.
REFERENCES:
patent: 2848430 (1954-10-01), Frey et al.
patent: 3629443 (1971-12-01), Lafon
patent: 4253322 (1981-03-01), Vydrin et al.
patent: 4263322 (1981-04-01), Van't Riet et al.
patent: 4623659 (1986-11-01), Van't Riet et al.
patent: 4814432 (1989-03-01), Freidinger et al.
patent: 4837304 (1989-06-01), Garsky et al.
patent: 4845195 (1989-07-01), Colonno et al.
patent: 5071835 (1991-12-01), Guindon et al.
patent: 5128353 (1992-07-01), Bergeron
patent: 5135917 (1992-08-01), Burch
patent: 5173505 (1992-12-01), Bergeron
patent: 5183828 (1993-02-01), Van't Riet et al.
patent: 5198425 (1993-03-01), Rakhit et al.
patent: 5292775 (1994-03-01), Bergeron
patent: 5294533 (1994-03-01), Lupski et al.
patent: 5391563 (1995-02-01), Bergeron
patent: 5466702 (1995-11-01), Bergeron
patent: 5476841 (1995-12-01), Deziel et al.
patent: 5496837 (1996-03-01), Bergeron
patent: 5496838 (1996-03-01), Bergeron
patent: 5496839 (1996-03-01), Bergeron
patent: 5496840 (1996-03-01), Bergeron
patent: 5496841 (1996-03-01), Bergeron
patent: 5498622 (1996-03-01), Bergeron
patent: 5508393 (1996-04-01), McCarthy et al.
patent: 5514695 (1996-05-01), Bergeron
patent: 5519041 (1996-05-01), Bergeron
patent: 5536738 (1996-07-01), Bergeron
patent: 5536739 (1996-07-01), Bergeron
patent: 5541207 (1996-07-01), Bergeron
patent: 5545649 (1996-08-01), Bergeron
patent: 5545650 (1996-08-01), Bergeron
patent: 5550144 (1996-08-01), Bergeron
patent: 5569666 (1996-10-01), Bergeron
patent: 5589587 (1996-12-01), McCarthy et al.
patent: 5627158 (1997-05-01), Ch-Chung
patent: 5641754 (1997-06-01), Iversen
patent: 5691317 (1997-11-01), Cho-Chung
patent: 5760210 (1998-06-01), McCarthy et al.
patent: 5767134 (1998-06-01), Li et al.
patent: 5780607 (1998-07-01), Goodnow, Jr. et al.
patent: 5786138 (1998-07-01), Swenson
patent: 5849903 (1998-12-01), Pietrzkowski et al.
patent: 5856103 (1999-01-01), Gray et al.
patent: 5869676 (1999-02-01), Niu et al.
patent: 5885830 (1999-03-01), Saeki et al.
patent: 5919772 (1999-07-01), Szyf et al.
patent: 5955590 (1999-09-01), Levina et al.
patent: 5990088 (1999-11-01), Ensoli et al.
patent: 5994320 (1999-11-01), Low et al.
patent: 5998383 (1999-12-01), Wright et al.
patent: 5998602 (1999-12-01), Torrence et al.
patent: 6005095 (1999-12-01), Capaccioli et al.
patent: 6007995 (1999-12-01), Baker et al.
patent: 6013522 (2000-01-01), Monia et al.
patent: 6017898 (2000-01-01), Pietrzkowski et al.
patent: 6018042 (2000-01-01), Mett et al.
patent: 6025198 (2000-02-01), Bennett et al.
patent: 6030942 (2000-02-01), Cooperman et al.
patent: 6033910 (2000-03-01), Monia et al.
patent: 6040296 (2000-03-01), Nyce
patent: 6046004 (2000-04-01), Wu et al.
patent: 6046319 (2000-04-01), Power et al.
patent: 6057437 (2000-05-01), Kamiya et al.
patent: 6121000 (2000-09-01), Wright et al.
patent: 6248782 (2001-06-01), Elford et al.
patent: 6291504 (2001-09-01), Nugiel et al.
patent: 6593305 (2003-07-01), Wright
patent: 2003/0024534 (2003-02-01), Silvestri et al.
patent: 2004/0126400 (2004-07-01), Iversen et al.
patent: 2009/0047250 (2009-02-01), Elford
patent: 32 37 253 (1983-10-01), None
patent: 44 36 127 (1996-03-01), None
patent: 1 362 511 (2003-11-01), None
patent: 1 481 669 (2004-12-01), None
patent: WO 94/00135 (1994-01-01), None
patent: WO 98/20864 (1998-05-01), None
patent: WO 99/06009 (1999-02-01), None
patent: WO 99/30699 (1999-06-01), None
patent: WO 01/10454 (2001-02-01), None
patent: WO 01/49281 (2001-07-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/055017 (2002-07-01), None
patent: WO 03/070188 (2003-08-01), None
patent: WO 03/103583 (2003-12-01), None
patent: WO 2004/006841 (2004-01-01), None
patent: WO 2004/080377 (2004-09-01), None
patent: WO 2005/027972 (2005-03-01), None
patent: WO 2005/115405 (2005-12-01), None
patent: WO 2005/123053 (2005-12-01), None
patent: WO 2006/128142 (2006-11-01), None
patent: WO 2007/104242 (2007-09-01), None
patent: WO 2007/128442 (2007-11-01), None
patent: WO 2008/021210 (2008-02-01), None
Sumpter et al. Proc. Amer. Assoc. Cancer Res., vol. 45, 2004.
Greenland et al., International J. of Epidemiology 2002; 31:1129-1134.
Sidney Blumenthal, The American Journal of Cardiology; vol. 31, Issue 5, May 1973, pp. 591-594.
Merriam Webster Dictionary entries for the terms: “prevent” and “restenosis” (2 entries).
International Preliminary Report on Patentability for PCT/US05/014581, filing date Apr. 27, 2005.
EP Search Report for EP08 25 2683 application dated Jun. 17, 2009.
Rubens et al. Phase II trial of didox in advanced breast cancer, Br. J. Cancer (1991), 64, 1187-1188.
LEUSTATIN® (cladribine) Injection for Intravenous Infusion Only, Ortho Biotech Products, L.P., Raritan, NJ 08869, Aug. 2007.
Campbell et al. Didox therapy for demyelinating diseaseJournal of Neurochemistry, vol. 102, Aug. 6, 2007, p. 145.
Database CA, Chemical Abstracts Service, Columbus, Ohio, Nov. 8, 1965,Treatment of diabetesXP002531119, Database accession No. 1967:40714.
Vincent et al. Identification of candidate drugs for the treatment of ALS, Amyothrophic Lateral Sclerosis, London, GB, vol. 6, No. 1, Jan. 1, 2005, pp. 29-36.
Database WPI Week 199702, Treating Parkinsonian syndrome—by treatment with haloperidol at a dilution of 2:1000000, Thomson Scientific, London, GB; AN 1997-019281, XP002531120.
Fang et al. Hypoglycemic activity and chemical structure of the salicylates.Journal of Pharmaceutical Sciences, vol. 57, No. 12, Dec. 1968, pp. 2111-2116.
Wyss-Coray and Mucke, Inflammation in Neurodegenerative Disease—A Double-Edged Sword, 2002 Neuron, 35: 419-432.
Basu, Kraddy, and Levison, Interleukin-1: A Master Regulator of Neuroinflammation 2004 Journal of Neuroscience Research, 78(2): 151-156.
Griffin, Inflammation and neurodegenerative diseases2006 American Journal of Clinical Nutrition, 83(Suppl): 470S-474S.
Honig, Inflammation in Neurodegenerative Disease, 2000 Archives of Neurology, 57(6): 786-788.
Weydt and Moller, Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis2005 Neuroreport, 16(6):527-531.
Hunot and Hirsch, Neuroinflammatory Processes in Parkinson's Disease2003 Annals of Neurology, 53(Suppl 3): S49-S58.
McGeer and McGeer, Local neuroinflammation and the progression of Alzheimer's disease2002 Journal of Neurovirol., 8(6): 529-538.
Hull and Hampel, 9 Neuroinflammation in Alzheimer's Disease: Potential Targets for Disease-Modifying Drugs 2002 Ernst Schering Res Found Workshop, (39): 159-178.
Pardo, Vargas, and Zimmernlan, Immunity, neuroglia and neuroinflammation in autism, 2005 International Review of Psychiatry, 17(6): 485-495.
Godbout and Johnson, Age and Neuroinflammation: A Lifetime of Psychoneuroimmune Consequences 2006 Neurologic Clinics, 24(3): 521-538.
Rooker et al., Spatiotemporal Pattern of Neuroinflammation After Impact-Acceleration Closed Head Injury in the Rat2006 Mediators Inflammation, 2006(1): 90123.
Molcanyi et al., Trauma-Associated Inflammatory Response Impairs Embryonic Stem Cell Survival and Integration after Implantation into Injured Rat Brain 2007 Journal of Neurotrauma, 24(4): 625-637.
Tang et al., Regulatory T-cell physiology and application to treat autoimmunity2006 Immunol Rev. 212:217-237.
Dorner et al. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets 2003 Curr. Opin. Rheumatol 15: 246-252.
Takemura et al. T Cell Activation in Rheumatoid Synovium is B Cell Dependent 2001 J Immunol 107: 4710-4718.
Cua et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain 2003 Nature 421: 744-748.
Murphy et al. Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation 2003 J. Exp Med. 198: 1951-1957.
Langrish et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation 2005 J. Exp Med. 201: 233-240.
Chen et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune ence
Cardounel Arturo J.
Elford Howard L.
Kilpatrick Townsend & Stockton LLP
Palenik Jeffrey
Wax Robert A
LandOfFree
Methods for treating or preventing restenosis and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating or preventing restenosis and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating or preventing restenosis and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258902